Biocartis Group NV
About Biocartis Group NV
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.
- Ticker
- BCART
- Trading on
- BR
- ISIN
- BE0974281132
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- CEO
- -
- Headquarters
- Generaal de Wittelaan 11 B, Mechelen, undefined, Belgium, 2800
- Employees
- 526
- Website
- biocartisgroupnv.be
Metrics
Earnings per share (EPS) forecast
| Q2 • 22 | Q3 • 22 | Q4 • 22 | |
|---|---|---|---|
| Actual | -€0.50 | - | -€0.79 |
| Expected | - | - | - |
| Surprise | - | - | - |
| Beat | Beat | Current |
Financial Performance
| Q1 • 23 | Q2 • 23 | QoQ growth | |
|---|---|---|---|
| Revenue | €14.8M | €29.5M | 99.15% |
| Net income | €-15.6M | €-31.3M | 100.00% |
| Profit margin | -105.53% | -105.98% | 0.43% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a Biocartis Group NV share?
Biocartis Group NV shares are currently traded for undefined per share.
02How many shares does Biocartis Group NV have?
Biocartis Group NV currently has 93.9M shares.
03Does Biocartis Group NV pay dividends?
No, Biocartis Group NV doesn't pay dividends.
04What is Biocartis Group NV 52 week high?
Biocartis Group NV 52 week high is €0.29.
05What is Biocartis Group NV 52 week low?
Biocartis Group NV 52 week low is €0.29.
06What is the 200-day moving average of Biocartis Group NV?
Biocartis Group NV 200-day moving average is €0.29.
07Who is Biocartis Group NV CEO?
The CEO of Biocartis Group NV is -.
08How many employees Biocartis Group NV has?
Biocartis Group NV has 526 employees.
09What is the market cap of Biocartis Group NV?
The market cap of Biocartis Group NV is €27.2M.
10What is the P/E of Biocartis Group NV?
The current P/E of Biocartis Group NV is null.
11What is the EPS of Biocartis Group NV?
The EPS of Biocartis Group NV is -€0.92.
12What is the PEG Ratio of Biocartis Group NV?
The PEG Ratio of Biocartis Group NV is null.


